Medical vs. Endovascular Treatment in Uncomplicated Type B Aortic Dissection

Under much debate, the treatment of uncomplicated type B aortic dissection is still uncertain. Several studies with methodological limitations have shown that endovascular treatment plus optimal medical treatment might be beneficial, compared with medical treatment alone.

Evaluación Hemodinámica de la Insuficiencia Aórtica post TAVR

This meta-analysis sought to define more clearly the treatment strategy in patients with acute and subacute uncomplicated type B aortic dissection. To that end, researchers conducted a systematic review and meta-analysis of observational studies and randomized trials.

The primary endpoints were early mortality and re-intervention, late all-cause and aorta-related mortality, and late re-intervention.


Read also: PASCAL in Tricuspid Regurgitation with Encouraging Results.


Researchers analyzed 6 studies with a total of 14,706 patients; 1066 of them underwent endovascular treatment.

There were no significant differences between endovascular treatment and medical treatment with regards to early mortality (p = 0.46), early re-interventions (p = 0.19), or surgery (p = 1).

Medical treatment was significantly associated with a lower risk of early stroke (p = 0.002) but a higher risk of late all-cause mortality (p < 0.001) and aorta-related mortality (p = 0.001), compared with endovascular treatment.

Conclusion

Given the limited number and, particularly, the limited quality of studies on endovascular treatment vs. medical treatment in patients with acute or subacute uncomplicated type B aortic dissection, a categorical recommendation remains uncertain. Further information is required to understand which dissections and patients would benefit from preventive treatment.

Original title: Endovascular vs. Medical Management for Uncomplicated Acute and Subacute Type B Aortic Dissection: A Meta-analysis.

Reference: Martin Hossack et al. Eur J Vasc Endovasc Surg. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Duration of Smoking Cessation and Risk of Amputation After Revascularization in Critical Limb Ischemia

Critical limb ischemia (CLI) is associated with high rates of amputation and mortality. Although smoking cessation improves outcomes after revascularization, the impact of the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...